.webp)
Acerca de
The Maximon Longevity Prize
The Maximon Longevity Prize for Translational Research awards outstanding breakthrough research in the field of longevity that can be translated for clinical or non-clinical applications and has the potential to substantially increase health span or life span of humans.
The award focuses on research that already has a proof of concept in pre-clinical lab studies to have a significant impact on the health optimization or longevity.
The Pledge
Maximon is on a mission to extend the health span and to allow people to be fit, healthy and happy until high-age.
We are accelerating longevity research by giving exceptional researchers the resources they need to expand their work and invest in new products and services geared to a longevity-society.
Maximon pledges 50 000 CHF for the winner.
The prize recipients will also receive additional benefits from sponsors such as:
-
Personalized longevity program sponsored by Biolytica at the value of 20 000 CHF
-
One-year subscription for science-based longevity supplements supplied by AVEA at the value of 5 000 CHF
jury 2023
Dr. Dr. Elisabeth Roider
Partner & Chief Scientific and Medical Officer at Maximon
Prof. Dr. Evelyne Yehudit Bischof, MD, MPH
Associate Professor at Shanghai University of Medicine&Health Sciences
Prof Andrea Maier, MD PhD FRACP
Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research
Dr. Nir Barzilai
Director, Einstein Institute for Aging Research at Albert Einstein College of Medicine
Prof. Dr. Collin Y. Ewald
Assistant Professor at ETH Zurich
Dr. Heike Bischoff-Ferrari
Professor of Geriatrics and Aging Research, UZH
Dr. Aubrey de Grey
President and CSO at LEV Foundation
Sebastien Thuault
Chief Editor of Nature Aging
Sophie Chabloz
Co-Founder and CPO at AVEA
timeline 2023
6th of April
2023
14th of July
2023
29th of September
2023
1st of September
2023
Longevity prize launch.
Applications are open
Application window is closed
End of Evaluation
phase
Award Ceremony at the LIC Gala Dinner
application
The application window is closed.
.png)
_edited.png){kind=logo}
-
What are the evaluation criteria?How much translation does the research have Longevity potential Feasibility Market potential Novelity
-
What are the areas of research that are covered by the prize?The Maximon Longevity Prize will be given to an inventor or scientist (could be a student), who either published the breakthrough research, holds the patent or in very advanced stages of research in one of the following topic areas: Biology of ageing and molecular pathways Physical health Disease prevention incl. biomarkers and indicators of disease Behavioral health (well-being, mental) Technology (AI, robotics, biotech, etc.)
-
Who owns the IP of the awarded project?The winner of the prize owns the IP. We make no claims on the intellectual property.
-
What is the evaluation process?Applications received through website and internal nominations will be assessed by our jury based on the above mentioned criterias and a score will be assigned on each criteria independently by each jury member. Based on the highest point cumulatively, the winner will be decided.
-
When will applications be opened?Applications will be opened on April 1st. To apply, follow this link (www.maximon.com/apply)
-
When will applications be closed?The application window will close on 31st of July.
-
How long is the evaluation phase?The evaluation of all applications will be reviewed by our Jury between 1st of August and end of September, when the winner of the prize will be announced.
-
When will the winner be announced?We will announce the winner during Maximon’s annual Longevity Investors Conference taking place on September 27-29th in Gstaad. We will host a Gala Dinner during which the winner will receive the prize. www.longevityinvestors.ch
-
How can I support this project?If you would like to donate or sponsor the project, please reach out to Elisabeth at elisabeth@maximon.com
-
Will my application be confidential?By applying, you're agreeing to your name and project title (but no further details) being shared with donors and the public.
team
Dr. Tobias Reichmuth
Founding Partner
Dr. Dr. Elisabeth Roider
Partner & Chief Scientific and Medical Officer
Eva Novak
Junior Event Coordinator